Physician profile
Christopher Mitchell
NPI 1972583375
$9,688.08
in general payments reported to CMS, 2019-2025
39 companies · $3,655 in 2025
The $3,655 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $517 · 2023: $2,365 · 2024: $3,151 · 2025: $3,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,974 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,974.27 |
| Education | $196.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,658.09 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $1,654.36 | 2022-2025 | Tezspire, Airsupra, Fasenra |
| Regeneron Healthcare Solutions, INC. | $878.84 | 2022-2025 | Dupixent |
| Csl Behring | $850.40 | 2023-2025 | Hizentra, Haegarda, Andembry |
| Genzyme Corporation | $834.27 | 2022-2025 | |
| Amgen INC. | $660.79 | 2022-2025 | Tezspire, Actimmune |
| Novartis Pharmaceuticals Corporation | $402.19 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $321.28 | 2024-2025 | Takhzyro, Eohilia, Glassia |
| Pfizer INC. | $318.93 | 2023-2025 | |
| Genentech USA, INC. | $236.75 | 2023-2025 | Xolair |
| Biocryst US Sales Co., LLC | $228.05 | 2023-2025 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $177.72 | 2025 | Neffy |
| Octapharma USA, INC. | $168.01 | 2024-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Phadia US INC. | $132.91 | 2023-2025 | Immunocap |
| Optinose US, INC. | $98.47 | 2023-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $94.22 | 2022 | |
| Grifols USA, LLC | $90.70 | 2024-2025 | Gamunex-C |
| Pharming Healthcare, INC. | $84.33 | 2023-2025 | Ruconest |
| Galderma Laboratories, L.P. | $76.61 | 2025 | Nemluvio |
| Blueprint Medicines Corporation | $69.24 | 2023-2025 | Ayvakit |
| Ionis Pharmaceuticals, INC. | $64.18 | 2025 | Dawnzera |
| Kaleo, INC. | $62.37 | 2023-2024 | Auvi-Q |
| Tersera Therapeutics LLC | $60.44 | 2024-2025 | Quzyttir |
| Sanofi-Aventis U.S. LLC | $54.95 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $48.38 | 2022-2023 | Airduo Digihaler |
| Invivyd INC | $42.94 | 2025 | Pemgarda |
| Cycle Pharmaceuticals INC | $40.65 | 2025 | Sajazir |
| Hikma Pharmaceuticals USA | $34.88 | 2022 | |
| Lilly USA, LLC | $33.17 | 2025 | Ebglyss |
| Horizon Therapeutics Plc | $31.22 | 2023 | Actimmune |
| Mylan Specialty L.P. | $26.28 | 2023 | Yupelri |
| Leo Pharma INC. | $24.95 | 2025 | Anzupgo |
| Covis Pharma Gmbh | $24.94 | 2022 | |
| Dermavant Sciences, INC. | $23.28 | 2024 | Vtama |
| Alk-Abello, INC | $19.80 | 2025 | Pre-Pen, Alternaria Tenuis, Timothy, Standardized |
| Merck Sharp & Dohme LLC | $16.29 | 2023 | |
| Baxter Healthcare | $15.74 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.92 | 2023 | Spiriva Respimat |
| Organon LLC | $12.54 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.